Galderma Repurchases CHF 232 Million in Shares as Major Investors Exit
Event summary
- Galderma repurchased 1.6 million shares at CHF 143.75 per share, totaling CHF 232 million in an accelerated bookbuild offering (ABO).
- The Selling Shareholders—Sunshine SwissCo GmbH (EQT), Abu Dhabi Investment Authority, and Auba Investment Pte. Ltd.—fully divested their remaining stake.
- The repurchase is financed by existing liquidity and will not impact Galderma’s strategic or financing priorities.
- Shares will be held in treasury for employee participation plans, business development, or treasury management.
- Free float of Galderma shares is expected to increase from 65% to 80%.
The big picture
Galderma’s share repurchase underscores its confidence in future growth, aligning with its strategy to solidify category leadership in dermatology. The exit of major investors marks a governance shift, potentially increasing liquidity and broadening the investor base. This move comes amid a broader trend of healthcare companies optimizing capital structures to enhance shareholder value.
What we're watching
- Capital Allocation Strategy
- How Galderma will deploy the repurchased shares for employee participation, business development, or treasury management.
- Market Impact
- Whether the increased free float will enhance liquidity and attract new institutional investors.
- Strategic Confidence
- The pace at which Galderma can sustain its growth ambitions while maintaining financial discipline post-repurchase.
Related topics